Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Juli 2018 01:00 ET | Quelle: Celyad SA

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

FDA acceptance of IND for world’s first non-gene edited allogeneic CAR-T clinical programFirst of a family of non-gene edited allogeneic CAR-T, targeting colorectal cancer to build on the experience...
19. Juni 2018 01:00 ET | Quelle: Celyad SA

Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial and Begins Dosing First Patient With Second Cycle of Therapy

Celyad advances THINK trial to third and final dose level in hematological study armSecond cycle treatment amendment in THINK protocol approved and first patient dosed MONT-SAINT-GUIBERT, Belgium,...
23. Mai 2018 01:00 ET | Quelle: Celyad SA

Celyad Announces Closing of Global Offering

MONT-SAINT-GUIBERT, Belgium, May 23, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the...
17. Mai 2018 09:02 ET | Quelle: Celyad SA

Celyad announces pricing of $47.3 million global offering

MONT-SAINT-GUIBERT, Belgium, May 17, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...
15. Mai 2018 16:47 ET | Quelle: Celyad SA

Celyad Announces First Quarter 2018 Business Update

Steady progress in THINK1, SHRINK2 and LINK3 trials MONT-SAINT-GUIBERT, Belgium, May 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a...
15. Mai 2018 16:46 ET | Quelle: Celyad SA

Celyad announces launch of proposed global offering

MONT-SAINT-GUIBERT, Belgium, May 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...
09. Mai 2018 01:00 ET | Quelle: Celyad SA

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

MONT-SAINT-GUIBERT, Belgium, May 09, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) a clinical-stage biopharmaceutical company focused on the development of...
03. Mai 2018 01:00 ET | Quelle: Celyad SA

Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials

Celyad achieves important milestone in CYAD-01 treatment evaluation of metastatic colorectal cancer: No toxicity observed to date in first patient enrolled in the SHRINK1 trial (concurrent...
27. April 2018 02:30 ET | Quelle: Celyad SA

Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient

Case report details first ever reported complete morphologic remission with gene engineered T-cells in a relapsed/refractory AML patient without preconditioning MONT-SAINT-GUIBERT, Belgium, April ...
29. März 2018 01:00 ET | Quelle: Celyad SA

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

MONT-SAINT-GUIBERT, Belgium, March 29, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...

Vorherige Seite